Applied DNA Sciences to Create Strategic Advisory Board

STONY BROOK, NY--(Marketwired - February 11, 2016) - Applied DNA Sciences, Inc. (NASDAQ: APDN) (Twitter: @APDN), a provider of DNA-based supply-chain, anti-counterfeiting and anti-theft technology, product genotyping and product authentication solutions, announced the formation of a Strategic Advisory Board (SAB) that will provide guidance and industry outreach in specific market verticals. Initially the SAB will be composed of two former executives with decades of experience in the pharmaceutical field who will assist the Company in its entry into the pharmaceutical industry, and a globally recognized leader of major energy utilities, who will guide the Company's expansion into the protection of critical infrastructure in power grids and railways.

Dr.James Hayward, President and CEO of Applied DNA stated, "As we continue to mature and develop our core vertical markets and venture into new emerging markets, we are pleased to announce the formation of a Strategic Advisory Board. This board will consist of globally recognized experts in their fields, who have a broad viewpoint and are respected leaders of change within their vertical markets. The board will provide insights and guidance to our strategic plans and help shape the direction of our company. It is with great pleasure that I announce our first three board members."

Bob Catell, Chairman New York State Smart Grid Consortium, Chairman, U.S., Advanced Energy Research and Technology Center at Stony Brook, Former Chairman of National Grid U.S., and former Chairman and CEO of KeySpan Corporation. Bob will guide our strategies for railways and power authorities across the globe. His impressive leadership abilities and worldwide perspective, will provide us with industry knowledge and a lens to forward thinking concepts which will optimize our solutions in these two emerging markets for APDN. Mr. Catell has agreed to Chair the Strategic Advisory Board.

Gunther Faber, former Vice President, Sub-Saharan Africa, for GlaxoSmithKline, has more than 30 years of experience working in the pharmaceutical industry. Gunther was also a member of the company's Policy Team on Access to Medicine. Gunther is currently the Chairman and Chief Executive Officer of One Family Health, a US501(c)(3) tax exempt Foundation and a L3C low profit company involved in developing a franchise network of entry level primary healthcare clinics in Africa. Gunther's experience working in Africa, which has a high concentration of pharmaceutical counterfeits, will provide critical perspective to educate leaders and create industry awareness linking our solutions to prevent the pharmaceutical supply chain from being compromised. 

Bob Miglani, serves as Senior Director, External Medical Affairs for Pfizer Inc., in New York City. Bob has been with Pfizer for 23 years, developing innovative partnerships with medical and healthcare organizations in the US and around the world in the area of health and wellness, new customer partnerships and public health. He is a thought leader who frequently speaks at business, scientific and healthcare forums, serving on the Public Health Foundation of India's Health Systems Reform Council, being an Advisor to the President of the American Association of Physicians of Indian origin (AAPI) and the World Medical Association (WMA). Bob's domain knowledge in the pharmaceutical sector will be invaluable as we expand our solutions into this vertical to combat the increasing counterfeiting issue that is threatening hundreds of thousands of lives a year across the globe.

Dr. Hayward continued, "Having these three distinguished professionals as an extension of our team will help us progress forward in these key markets."

About Applied DNA Sciences

Applied DNA Sciences makes life real and safe by providing biotechnology-driven solutions to help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Patented botanical DNA solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature DNA is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators.

Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW. 

Forward Looking Statements

The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, and our subsequent quarterly report on Form 10-Q filed on February 10, 2016, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

web: www.adnas.com

twitter: @APDN